FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION +----------------------------------+------------------------------------------+ |(a) Identity of the party to the |ASTRAZENECA PLC | |offer making the disclosure: | | +----------------------------------+------------------------------------------+ |(b) Owner or controller of |N/A | |interests and short positions | | |disclosed, if different from | | |1(a): The naming of nominee or| | |vehicle companies is insufficient | | +----------------------------------+------------------------------------------+ |(c) Name of offeror/offeree in |ASTRAZENECA PLC (OFFEREE) | |relation to whose relevant | | |securities this form relates: | | |Use a separate form for each party| | |to the offer | | +----------------------------------+------------------------------------------+ |(d) Is the party to the offer |OFFEREE | |making the disclosure the offeror | | |or the offeree? | | +----------------------------------+------------------------------------------+ |(e) Date position held: |12 MAY 2014 | +----------------------------------+------------------------------------------+ |(f) Has the party previously |YES: PFIZER INC. (OFFEROR)DISCLOSING TODAY| |disclosed, or is it today | | |disclosing, under the Code in | | |respect of any other party to this| | |offer? | | +----------------------------------+------------------------------------------+ 2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates +------------------------------------------------+---------+-+---------------+-+ |Class of relevant security: | | | | | +------------------------------------------------+---------+-+---------------+-+ | |Interests| |Short positions| | +------------------------------------------------+---------+-+---------------+-+ | |Number |%|Number |%| +------------------------------------------------+---------+-+---------------+-+ |(1) Relevant securities owned and/or controlled:|Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ |(2) Derivatives (other than options): |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ |(3) Options and agreements to purchase/sell: |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ | TOTAL: |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ All interests and all short positions should be disclosed. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL). (b) Rights to subscribe for new securities +---------------------------------------------------------------------------+--- -+ |Class of relevant security in relation to which subscription right exists: |None| +---------------------------------------------------------------------------+--- -+ |Details, including nature of the rights concerned and relevant percentages:|None| +---------------------------------------------------------------------------+--- -+ If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (c) Irrevocable commitments and letters of intent +-----------------------------------------------------------------------------+ |Details of any irrevocable commitments or letters of intent procured by the | |party to the offer making the disclosure or any person acting in concert with| |it (see Note 3 on Rule 2.11 of the Code): | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ 3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE +---------------------------------------------------------------------------+ |Details of any interests, short positions and rights to subscribe of any | |person acting in concert with the party to the offer making the disclosure:| +---------------------------------------------------------------------------+ 3(a) Shares held by directors of AstraZeneca PLC +-----------+-----------+--------------------------------------------+ |Director |Number of |Percentage of total issued share capital (%)| | |AstraZeneca| | | |Shares | | +-----------+-----------+--------------------------------------------+ |Pascal |151,581 |0.01200826 | |Soriot | | | +-----------+-----------+--------------------------------------------+ |Marc |500 |0.00003961 | |Dunoyer | | | +-----------+-----------+--------------------------------------------+ |Leif |33,009 |0.002614976 | |Johansson | | | +-----------+-----------+--------------------------------------------+ |Genevieve |1,790 |0.000141804 | |Berger | | | +-----------+-----------+--------------------------------------------+ |Bruce |2,249 |0.000178166 | |Burlington | | | +-----------+-----------+--------------------------------------------+ |Ann Cairns |1,225 |0.000097044 | +-----------+-----------+--------------------------------------------+ |Graham |1,900 |0.000150518 | |Chipchase | | | +-----------+-----------+--------------------------------------------+ |Jean |2,635 |0.000208745 | |-Philippe | | | |Courtois | | | +-----------+-----------+--------------------------------------------+ |Rudy |2,452 |0.000194248 | |Markham | | | +-----------+-----------+--------------------------------------------+ |Nancy |2,643 |0.000209379 | |Rothwell | | | +-----------+-----------+--------------------------------------------+ |Shriti |3,000 |0.00023766 | |Vadera | | | +-----------+-----------+--------------------------------------------+ |John Varley|9,500 |0.000752591 | +-----------+-----------+--------------------------------------------+ |Marcus |63,646 |0.005042042 | |Wallenberg | | | +-----------+-----------+--------------------------------------------+ 3(b) Directors’ interests in awards of AstraZeneca PLC shares under AstraZeneca PLC’s share plans Deferred Bonus Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |3,799 |25/02/2013 |2939 |25/02/2016 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |15,966 |28/03/2014 |3904 |28/03/2017 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |2,679 |28/03/2014 |3904 |28/03/2017 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ Performance Share Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |125,113 |11/06/2013 |3297 |11/06/2016 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |124,066 |28/03/2014 |3904 |28/03/2017 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |90,853 |01/08/2013 |3302 |01/08/2016 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |52,254 |28/03/2014 |3904 |28/03/2017 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ AstraZeneca Investment Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |89,960 |11/06/2013 |3297 |01/01/2021 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,677 |28/03/2014 |3904 |01/01/2022 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |8,176 |01/08/2013 |3302 |01/01/2021 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |8,709 |28/03/2014 |3904 |01/01/2022 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ Restricted Share Award +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,732 |26/10/2012 |2894 |01/10/2014 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,732 |26/10/2012 |2894 |01/10/2015 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ Restricted Share Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |9,103 |01/08/2013 |3302 |15/06/2014 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |41,472 |01/08/2013 |3302 |15/06/2015 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |14,930 |01/08/2013 |3302 |01/08/2016 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ 3(c) Interests of connected advisers Goldman, Sachs & Co Class of relevant security: USD 0.25 ordinary and ADRs Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 15,066 0.00 222,448 0.01 (2) Derivatives (other than options): 0 0.00 0 0.00 (3) Options and agreements to purchase/sell: 205,600 0.02 177,900 0.01 TOTAL: 220,666 0.02 400,348 0.03 Morgan Stanley B.V. Class of relevant USD 0.25 ordinary and ADRs security: Interests Short positions Number % Number % (1) Relevant securities 0 0.00 0 0.00 owned and/or controlled: (2) Derivatives (other 0 0.00 0 0.00 than options): (3) Options and 6,883 0.00 0 0.00 agreements to purchase/sell: TOTAL: 6,883 0.0005 0 0.00 3(d) Interests of employment benefit trusts +--------------------+-----------+----------------------------------------+ |Entity |Number of |Percentage of existing issued shares (%)| | |AstraZeneca| | | |Shares | | +--------------------+-----------+----------------------------------------+ |AstraZeneca Employee|1,051,810 |0.083324481 | |Share Trust Limited | | | +--------------------+-----------+----------------------------------------+ |AstraZeneca Share |100 |0.000007922 | |Trust Limited | | | +--------------------+-----------+----------------------------------------+ If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL). 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements +-----------------------------------------------------------------------------+ |Details of any indemnity or option arrangement, or any agreement or | |understanding, formal or informal, relating to relevant securities which may | |be an inducement to deal or refrain from dealing entered into by the party to| |the offer making the disclosure or any person acting in concert with it:If | |there are no such agreements, arrangements or understandings, state “none” | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ (b) Agreements, arrangements or understandings relating to options or derivatives +-----------------------------------------------------------------------------+ |Details of any agreement, arrangement or understanding, formal or informal, | |between the party to the offer making the disclosure, or any person acting in| |concert with it, and any other person relating to:(i) the voting rights of | |any relevant securities under any option; or (ii) the voting rights or future| |acquisition or disposal of any relevant securities to which any derivative is| |referenced:If there are no such agreements, arrangements or understandings, | |state “none” | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ (c) Attachments Are any Supplemental Forms attached? +------------------------------------+---+ |Supplemental Form 8 (Open Positions)|YES| +------------------------------------+---+ |Supplemental Form 8 (SBL) |NO | +------------------------------------+---+ +-------------------+------------------------------+ |Date of disclosure:|12 May 2014 | +-------------------+------------------------------+ |Contact name: |Adrian Kemp, Company Secretary| +-------------------+------------------------------+ |Telephone number: |020 7604 8000 | +-------------------+------------------------------+ Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. SUPPLEMENTAL FORM 8(OPEN POSITIONS) DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO PURCHASE OR SELL ETC. Note 5(i) on Rule 8 of the Takeover Code (the “Code”) 1. KEY INFORMATION Identity of the person whose open GOLDMAN, SACHS & CO. positions are being disclosed: Name of offeror/offeree in relation to ASTRAZENECA PLC (OFFEREE) whose relevant securities disclosure relates: 2. OPTIONS AND DERIVATIVES Class of Product Written Number of Exercise Typee.g. Expiry relevant description or securities to price American, date security e.g. purchased which per European call option option or unit etc. derivative relates USD 0.25 Call Option Sold 100 75.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Sold 200 45.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 200 75.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 200 80.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 300 72.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 500 80.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 600 60.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 600 67.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 600 70.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Sold 800 67.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Sold 1,000 90.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,100 65.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Sold 1,100 70.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,200 72.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Sold 1,300 62.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 1,300 67.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 1,600 65.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 1,600 67.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,700 62.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 1,800 70.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,800 75.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,000 55.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 2,000 70.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,400 77.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 2,600 67.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,700 57.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 2,800 65.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Purchased 2,800 72.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,900 77.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Sold 3,100 60.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Purchased 3,100 75.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 3,300 75.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 3,300 85.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 3,500 72.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 4,600 65.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 5,400 75.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 7,100 72.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Sold 7,400 70.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 9,400 80.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 11,100 65.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 18,100 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 21,900 70.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 32,500 80.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 33,300 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 100 35.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 100 40.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 100 40.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 100 47.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 200 30.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 200 37.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 300 60.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 300 70.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 300 75.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 500 52.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 600 57.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 600 65.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 800 67.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 900 27.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 900 32.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 900 70.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 55.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 60.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 1,000 75.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 1,100 70.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 1,200 67.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 1,200 72.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Sold 1,300 40.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 2,100 30.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 2,100 50.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 2,100 65.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 2,300 52.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 2,400 35.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 2,600 57.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 2,600 65.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 3,100 67.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 3,600 70.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 3,900 52.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Sold 4,100 70.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 4,300 60.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 4,700 42.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,000 25.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,100 47.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,200 45.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,900 62.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 5,900 62.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 6,400 50.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 7,100 65.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 7,500 60.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 7,600 67.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 8,400 65.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 8,600 55.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 10,000 55.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 10,400 62.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 11,600 57.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 16,300 62.5000 AMER 21/06/2 ordinary USD 014 3. AGREEMENTS TO PURCHASE OR SELL Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets The currency of all pieces and other monetary amounts should be stated. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. SUPPLEMENTAL FORM 8 (OPEN POSITIONS) DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC. Note 5(i) on Rule 8 of the Takeover Code (the “Code”) 1. KEY INFORMATION +--------------------------------------------+-------------------------+ |Identity of person whose open positions are |MORGAN STANLEY B.V. | |being disclosed: | | +--------------------------------------------+-------------------------+ |Name of offeror/offeree in relation to whose|ASTRAZENECA PLC (OFFEREE)| |relevant securities the disclosure relates: | | +--------------------------------------------+-------------------------+ 2. OPTIONS AND DERIVATIVES +--------+-----------+---------+-------------+---------+-------------+-------+ |Class of|Product |Written |Number of |Exercise |Typee.g. |Expiry | |relevant|description|or |securities to|price per|American, |date | |security|e.g. |purchased|which |unit |European etc.| | | |call option| |option or | | | | | | | |derivative | | | | | | | |relates | | | | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |1,737 |SEK 336.9|European |26/11/2| |ordinary| | | | | |015 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |610 |SEK 307.4|European |23/11/2| |ordinary| | | | | |017 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |1,956 |SEK 301.9|European |11/5/20| |ordinary| | | | | |16 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |2,580 |SEK 307.9|European |23/10/2| |ordinary| | | | | |017 | +--------+-----------+---------+-------------+---------+-------------+-------+ 3. AGREEMENTS TO PURCHASE OR SELL ETC. +---------------------------------------------------------------------------+ |Full details should be given so that the nature of the interest or position| |can be fully understood: | +---------------------------------------------------------------------------+ | | +---------------------------------------------------------------------------+ It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences (“CFDs”) or spread bets. The currency of all prices and other monetary amounts should be stated. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Form 8 (OPD) AstraZeneca PLC
| Source: AstraZeneca PLC